Flu shots given in the arm are good at preventing severe illness and much less reliable at stopping the virus from taking hold in the nose and lungs in the first place. New research points to an unexpected reason and a possible way around it.
Scientists at the University of Rochester have identified a population of immune cells in the lung that persists for more than four months after influenza infection, when the textbook says those cells should be gone within days. The cells are monocytes, part of the innate immune system, and the study finds they do not simply linger. Deleting them selectively reduced the formation of the lung's frontline memory T cells and compromised protection against a second, different strain of flu.
The work appears in Nature Immunology, published Monday, with Kihong Lim as first author and Minsoo Kim, a professor of microbiology and immunology, directing the study. One qualifier belongs before anything else: the functional findings were demonstrated in mouse models, and considerable work stands between them and any human vaccine.
The Defense Line That Injected Vaccines Miss
The lung maintains its own garrison. Tissue-resident memory T cells sit permanently in lung tissue rather than circulating in blood, positioned at the exact surface where respiratory viruses arrive.
"These cells are positioned right where infection begins, so they can react immediately and help limit viral spread," Kim said in a statement from the university. "They are a central goal for next-generation vaccine design because they provide fast, local protection in the respiratory tract."
The problem is that a vaccine delivered into arm muscle is efficient at generating antibodies in the bloodstream and inefficient at building durable memory in the airway. That mismatch helps explain a pattern many people have experienced personally: getting a flu shot, then getting flu anyway, but not badly. Nasal vaccines were designed to close that gap by delivering the vaccine where the virus lands, and their performance has been inconsistent.
The Molecule Doing the Communicating
The research traced how the long-lived monocyte-derived cells talk to memory T cells. They sit alongside those T cells in lung tissue and secrete a protein called galectin-1, which activates the T cells directly and makes them more sensitive to transforming growth factor beta, a signal that helps keep resident memory cells in place.
When the team added recombinant galectin-1 to an intranasal live attenuated influenza vaccine given to mice, using the same class of nasal vaccine sold commercially, the memory T cell response in the lungs was markedly stronger.
"Our work identified a long-lived monocyte-derived population in the lung that provides essential support for durable T cell immunity," Kim said. "This challenges the traditional view that immune memory is driven only by T and B cells, and shows that innate immune cells also play a lasting role."
That reframing is the scientific contribution. Immunology has long divided labor between an innate system that responds fast and forgets and an adaptive system that responds slowly and remembers. This work suggests the boundary is softer than taught, and that a vaccine could in principle be designed to recruit both sides of it at once. The journal published an accompanying commentary from independent immunologists, one of whom also reviewed the paper, under the title "Good neighbors make lasting memory."
The Distance Between a Mouse Lung and a Pharmacy Shelf
Nothing here changes what anyone should do this flu season. Seasonal vaccination remains the most effective available way to reduce the risk of serious influenza, and current vaccines are genuinely good at preventing hospitalization and death even when they do not prevent infection. Influenza kills thousands of Americans in a typical season, with the heaviest burden falling on older adults, young children, pregnant people, those with weakened immune systems and people with chronic heart, lung and metabolic conditions.
The gap between this finding and a product is wide and populated by failures. Adjuvants, the class of ingredient galectin-1 would belong to, must clear safety review before efficacy is even tested, and immune stimulating molecules draw particular scrutiny because the same signal that strengthens protection can drive inflammation. Galectin-1 is not obscure either. It has been studied in cancer biology, where blocking it is sometimes the goal, a reminder that a protein useful in one tissue context can behave differently in another.
Species differences also matter here, and the paper does not paper over them. The functional experiments, including the depletion studies and the vaccine work, were done in mice. The team did image human lung tissue containing resident memory T cells, but whether the same long-lived monocyte-derived population exists and behaves the same way in people is an open question that only human data can settle. The researchers deposited their sequencing datasets publicly through the Gene Expression Omnibus, which allows other groups to test the findings independently.
The work was funded by the National Institute of Allergy and Infectious Diseases, the National Heart, Lung and Blood Institute and other National Institutes of Health components, along with Korean research funding. The authors declare no competing interests.
The Practical Version for This Season
For households, the useful reading is about expectations rather than actions. A flu shot that does not prevent every infection is not a failed flu shot. It is a vaccine doing the job it was designed for, in the compartment it can reach.
People at higher risk have the most to gain from vaccination and the most reason not to wait for a better version that may be a decade away. Anyone who does catch flu should know that antiviral treatment started early is a separate and more immediately available lever than any future vaccine design.
Beyond influenza, the mechanism may prove relevant to other respiratory viruses. That is a hypothesis, not a result, and this study tested influenza only.
What to watch for next: whether galectin-1 or a stabilized derivative enters formal preclinical safety testing, and whether the long-lived monocyte population described in mice can be identified and characterized in human lung tissue. Until then, this is a promising mechanism, not a treatment, and it should be described that way.
Key Questions Answered
What did the researchers find? A subset of monocytes, immune cells normally considered short-lived, can persist in the lung for more than four months after influenza infection. Removing them reduced the formation of lung resident memory T cells and weakened protection against a second flu strain.
Was this study done in people? The functional experiments were done in mice. The team imaged human lung tissue containing resident memory T cells, but whether the same long-lived monocyte population exists in humans has not been established.
What is galectin-1? A protein secreted by the long-lived lung cells the team identified. It activates memory T cells directly and enhances their sensitivity to a signal that keeps them in tissue. Added to a nasal flu vaccine in mice, it produced a stronger lung memory response.
Does this mean current flu vaccines do not work? No. Injected flu vaccines are effective at preventing severe illness, hospitalization, and death. They are less reliable at preventing the virus from establishing infection in the nose and lungs, which is the gap this research addresses.
Should anyone delay a flu shot because of this? No. Seasonal vaccination remains the most effective available protection against serious influenza. Any vaccine built on this research is years away at minimum.
What happens next? The findings would need to be reproduced in human tissue, and any galectin-1-based adjuvant would have to clear preclinical safety testing before efficacy trials could begin. The team has made its sequencing data public so other groups can test the results.
